Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, ...

Hims & Hers Health, Inc. (HIMS) is expected to deliver a year-over-year increase in earnings on higher revenues when it ...

Virtual healthcare is rapidly evolving, led by Hims & Hers Health, Inc. HIMS and Teladoc Health, Inc. TDOC. HIMS offers a ...

Hims & Hers Health, Inc. (HIMS) closed at $58.68 in the latest trading session, marking a +1.79% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.02%.

Hims & Hers Health, Inc. HIMS has seen a surge in retail investor interest, which positions it as one of the most ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.